Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Epitopes

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Epitopes. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2019-001731-31 Sponsor Protocol Number: YFV_001 Start Date*: 2019-09-02
    Sponsor Name:Aarhus University Hospital
    Full Title: Cytotoxicity of Yellow Fever specific CD8 T cells Following YF-17D Vaccination
    Medical condition: Healthy individuals or HIV-1 infected individuals
    Disease: Version SOC Term Classification Code Term Level
    22.0 10022891 - Investigations 10022891 Investigations SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001431-27 Sponsor Protocol Number: CovidVal01 Start Date*: 2020-06-05
    Sponsor Name:Klinikum St. Georg gGmbH
    Full Title: Treatment of Sars-CoV2 infections (Covid-19) in patients without or with chronic kidney disease (CKD) with valsartan vs placebo, a three-armed randomized, partly blinded trial
    Medical condition: Sars-Cov2 infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000365-33 Sponsor Protocol Number: CHDR2043 Start Date*: 2021-03-17
    Sponsor Name:Molecular Partners AG
    Full Title: A Phase 2a open label, non-comparative, single dose escalation study to evaluate the dynamics of viral clearance, pharmacokinetics and tolerability of ensovibep in patients with symptomatic COVID-1...
    Medical condition: SARS-CoV-2 infection (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001070-38 Sponsor Protocol Number: B-pVAC-SARS-CoV-2 Start Date*: 2021-06-21
    Sponsor Name:University Hospital Tuebingen
    Full Title: B-pVAC-SARS-CoV-2: Phase I/II multi-center safety and immungenicity trial of multi-peptide vaccination to prevent COVID-19 infection in adults with B-cell/antibody deficiency
    Medical condition: Adults with congenital or acquired B cell/antibody deficiency
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000296-36 Sponsor Protocol Number: ZWI-ZW25-301 Start Date*: 2021-11-17
    Sponsor Name:Zymeworks Inc.
    Full Title: A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gast...
    Medical condition: Gastroesophageal Adenocarcinoma (GEA)
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10082464 Advanced gastric carcinoma LLT
    21.1 100000004864 10055458 Esophageal adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) IE (Trial now transitioned) IT (Trial now transitioned) EE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002571-16 Sponsor Protocol Number: MBP8298-01 Amendment 04 Start Date*: 2007-06-29
    Sponsor Name:BioMS Technology Corp
    Full Title: A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis.
    Medical condition: Secondary progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063400 Secondary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) FI (Completed) DK (Completed) ES (Completed) EE (Completed) NL (Completed) LT (Prematurely Ended) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001250-21 Sponsor Protocol Number: 2020/3078 Start Date*: 2020-04-03
    Sponsor Name:GUSTAVE ROUSSY
    Full Title: COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients
    Medical condition: Patients eligible for, or under, or recently treated by chemotherapy (CT) and/or immune-checkpoint blockade (ICB) for the treatment of solid tumors or hematological malignancies.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000219-24 Sponsor Protocol Number: 3082A-101342 Start Date*: 2005-04-28
    Sponsor Name:Wyeth Pharmaceuticals
    Full Title: A multicentre study to describe the immunogenic epitope(s) of factor VIII in previously treated patients with congenital haemophilia A who develop de novo factor VIII inhibitors while receiving fac...
    Medical condition: Haemophilia A is an X-linked recessive clotting disorder in which the clotting factor, factor VIII (FVIII), is deficient or inactive. Patients with low levels of FVIII have an increased tendency t...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) DE (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003188-90 Sponsor Protocol Number: ENFORCE-PLUS Start Date*: 2021-07-01
    Sponsor Name:CHIP - Rigshospitalet - University of Copenhagen
    Full Title: A Phase IV Vaccine Study under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE PLUS)
    Medical condition: The primary objective of the study is to assess if the SARS-CoV-2 vaccine Johnson & Johnson/Janssen results in change in number and activation of platelets and anti-PF4 level. As well as to compare...
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004669-15 Sponsor Protocol Number: CP007A Start Date*: 2014-06-16
    Sponsor Name:Circassia Limited
    Full Title: An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years after the Administration of Treatment
    Medical condition: Treatment of cat allergen induced rhinoconjunctivitis in patients with clinically relevant symptoms
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10034382 Perennial allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000890-10 Sponsor Protocol Number: MP0420-CP302 Start Date*: 2021-05-03
    Sponsor Name:Molecular Partners AG
    Full Title: A randomized, double-blind, placebo-controlled, multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19
    Medical condition: Symptomatic COVID-19 in ambulatory patients
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018341-56 Sponsor Protocol Number: VAC039 Start Date*: 2010-05-07
    Sponsor Name:University of Oxford
    Full Title: A phase I/IIa sporozoite challenge study to assess the safety, immunogenicity and protective efficacy of new malaria vaccine candidates; AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP...
    Medical condition: Malaria (plasmodium falciparum)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000547-24 Sponsor Protocol Number: CCRG11-001 Start Date*: 2012-02-27
    Sponsor Name:Antwerp University Hospital
    Full Title: Therapeutic efficacy of Wilms' tumor gene (WT1) mRNA-electroporated autologous dendritic cell vaccination in patients with solid tumors: a phase I/feasibility study
    Medical condition: Therapeutic vaccination with dendritic cells loaded with Wilms' tumor 1 protein in patients with solid tumors
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    14.0 10042613 - Surgical and medical procedures 10046859 Vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-006003-42 Sponsor Protocol Number: ENFORCE Start Date*: 2020-12-30
    Sponsor Name:CHIP - Rigshospitalet - University of Copenhagen
    Full Title: National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE)
    Medical condition: The aim is to study primarily effectiveness as well as safety of citizens being vaccinated with one of the SARS-CoV2 vaccines being applied in the Danish COVID-19 vaccine programme. Whereas ongoi...
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-002687-41 Sponsor Protocol Number: TA-8995-AD-1 Start Date*: 2021-12-09
    Sponsor Name:NewAmsterdam Pharma BV
    Full Title: A Phase 2a, Proof-of-Concept, Open-Label Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Obicetrapib in Patients with Early Alzheimer’s Disease (Hetero/Homozygote APOE4 Carr...
    Medical condition: Alzheimer's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003666-13 Sponsor Protocol Number: VAC89220HPX3002 Start Date*: 2019-10-15
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1...
    Medical condition: Prevention of HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Restarted) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003164-27 Sponsor Protocol Number: TW001-AD-C2.01 Start Date*: 2022-06-28
    Sponsor Name:Treeway TW001AD B.V.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of TW001 in Alzheimer Patients
    Medical condition: Alzheimer´s Disease (AD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015884-15 Sponsor Protocol Number: IMPAACT-P1066 Start Date*: 2011-06-30
    Sponsor Name:The National Institute of Allergy and Infectious Diseases (NIAID) and The Eunice Kennedy Shriver NICHD
    Full Title: A Phase I/II, Multicenter, Open-Label, Non comparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmac...
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-003102-14 Sponsor Protocol Number: IFG-NIB-01 Start Date*: 2017-09-19
    Sponsor Name:Institut für Frauengesundheit GmbH
    Full Title: A PHASE II ONE-ARM OPEN-LABEL NEOADJUVANT STUDY OF PEMBROLIZUMAB IN COMBINATION WITH NAB-PACLITAXEL FOLLOWED BY PEMBROLIZUMAB IN COMBINATION WITH EPIRUBICIN AND CYCLOPHOSPHAMIDE IN PATIENTS WITH TR...
    Medical condition: Female patients with early, neoadjuvantly treated, triple negative breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021976 Inflammatory breast cancer stage IV LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071115 Node-negative breast cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071113 Node-positive breast cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021974 Inflammatory breast cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021975 Inflammatory breast cancer stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063103 Tubular breast cancer stage I LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006194 Breast cancer NOS stage I LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063104 Tubular breast cancer stage II LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006196 Breast cancer NOS stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063102 Tubular breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006195 Breast cancer NOS stage II LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006190 Breast cancer invasive NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006192 Breast cancer NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063105 Tubular breast cancer stage III LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006199 Breast cancer stage I PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054784 Contralateral breast cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021944 Infiltrating ductal breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073289 Premenopausal breast cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022882 Invasive ductal breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006283 Breast neoplasm malignant female LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000827-94 Sponsor Protocol Number: U-DANCE-anti-AML Start Date*: 2016-09-08
    Sponsor Name:UMC Utrecht
    Full Title: A phase I/II post cord blood HCT dendritic cells vaccination trial directed against WT1 for pediatric acute myeloid leukemia: the U-DANCE-anti-AML trial
    Medical condition: AML: Acute Myeloid leukemia/ cancer of blood and bone marrow
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10000886 Acute myeloid leukemia LLT
    19.0 100000004864 10000887 Acute myeloid leukemia in remission LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Not Authorised)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 12:11:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA